spirapril

structure given in first source

Also Known As:

Quadropril; Renormax; Renpress; SCH 33844; SCH-33844; spirapril hydrochloride; 1,4-Dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8S-(7(R*(R*)),8R*))-

Networked: 76 relevant articles (13 outcomes, 26 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - Enalapril: 3647
        spirapril: 76

Experts

1.	Schmidt, J: 2 articles (12/2002 - 01/2000)
2.	Alimova, E V: 2 articles (01/2000 - 01/2000)
3.	Deev, A D: 2 articles (01/2000 - 01/2000)
4.	Koniakhina, I P: 2 articles (01/2000 - 01/2000)
5.	Kutishenko, N P: 2 articles (01/2000 - 01/2000)
6.	Martsevich, S Iu: 2 articles (01/2000 - 01/2000)
7.	Semenova, Iu E: 2 articles (01/2000 - 01/2000)
8.	Shal'nova, S A: 2 articles (01/2000 - 01/2000)
9.	Alonso, Ignacio: 1 article (05/2010)
10.	Ayala, Diana E: 1 article (05/2010)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1994 - "In conclusion, the studied dosages of spirapril were equally effective in reducing DBP, and the overall good decrease in blood pressure at the end of the dosing interval indicates that once-daily administration is effective in patients with mild-to-moderate hypertension." 08/01/1999 - "The efficacy and tolerability of spirapril were evaluated in a prospective, multicentre, post-marketing surveillance study on the treatment of arterial hypertension in 5000 patients, most of whom had received a single daily dose of 6 mg spirapril. " 01/01/1996 - "According to our study, spirapril 3mg seems to be a suitable starting dose for the treatment of hypertension in the elderly patients." 05/01/1995 - "In dose-finding studies of patients with mild to severe hypertension, spirapril > or = 6 mg once daily produced reductions in blood pressure of approximately 10 to 18 mm Hg (systolic) and 7 to 13 mm Hg (diastolic) [24-hour postdose trough readings at the end of the treatment period]. " 01/01/1994 - "UK Study Group of Spirapril in Hypertension."
2.	Essential Hypertension 08/01/1999 - "In several studies, spirapril was given to patients with mild-to-moderate essential hypertension at doses of 1-24 mg/day. " 01/01/1994 - "In a double-blind, parallel-group study, 260 patients with mild to severe essential hypertension were randomized to treatment with placebo or spirapril at 6, 12 or 24 mg once daily for 6 weeks. " 01/01/1994 - "A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. " 05/01/2010 - "Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension." 03/01/1996 - "These results indicate that spirapril lowers A/E ratio within four weeks in patients with mild to moderate essential hypertension. "
3.	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/01/2007 - "To study effects of two hypotensive drugs--normodipin and spirapril--on intravascular activity of platelets in patients with metabolic syndrome (MS). " 01/01/2007 - "[A comparative analysis of normodipin and spirapril effects on intravascular activity of platelets in patients with metabolic syndrome]." 01/01/2006 - "Thus spirapril and moexipril are effective in treatment of hypertension in patients with postmenopausal metabolic syndrome." 01/01/2006 - "Moexipril (7.4-15 mg/day) was given to 34, spirapril (3-6 mg/day) -- to 18 postmenopausal women with hypertension and metabolic syndrome for 16 weeks. " 01/01/2006 - "Patients with postmenopausal metabolic syndrome had elevation of leptin level up to 27.5+/-5.5 pg/ml. Moexipril and spirapril caused lowering of elevated levels of leptin. "
4.	Heart Failure 01/01/1996 - "Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure." 10/01/1991 - "From our findings we conclude that 1.5 mg spirapril is an optimal starting dose in patients with moderate to severe congestive heart failure." 10/01/1991 - "The results indicate that spirapril may be expected to be an effective drug in the treatment of congestive heart failure. " 10/01/1991 - "The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure." 06/01/1997 - "[Therapy of heart failure with spirapril--the open phase of the CASSIS study. "
5.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/1994 - "Spirapril in chronic renal failure." 08/01/1999 - "ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril." 08/15/1994 - "[Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril]." 01/01/1994 - "Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure." 05/01/2001 - "The aim of the study was to evaluate the rate of decline in GFR in patients with chronic renal failure and hypertension treated with isradipine and spirapril as monotherapy and in combination. "

Related Drugs and Biologics

1.	Antihypertensive Agents (Antihypertensives)
2.	Isradipine (Dynacirc)
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
4.	spirapril
5.	Enalapril
6.	Captopril (Capoten)
7.	Nifedipine (Adalat)
8.	moexipril (Perdix)
9.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
10.	Hydrochlorothiazide (Esidrix)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration